Cytek Biosciences Inc

For the period ended Mar 31, 2024. Filed May 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

CTKB$5.79-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Three months ended March 31,
(In thousands, except share and per share data)	2024	2023
Revenue, net:
Product	$34,122	$31,172
Service	10,738	5,916
Total revenue, net	44,860	37,088
Cost of sales:
Product	16,746	12,677
Service	5,101	3,373
Total cost of sales	21,847	16,050
Gross profit	23,013	21,038
Operating expenses:
Research and development	9,796	9,974
Sales and marketing	12,543	11,145
General and administrative	11,408	12,081
Total operating expenses	33,747	33,200
Loss from operations	(10,734)	(12,162)
Other income (expense):
Interest expense	(441)	(673)
Interest income	1,359	2,143
Other income, net	823	1,652
Total other income, net	1,741	3,122
Loss before income taxes	(8,993)	(9,040)
Benefit from income taxes	(2,824)	(2,233)
Net loss	(6,169)	(6,807)
Net loss, basic and diluted	$(6,169)	$(6,807)
Net loss per share, basic	$(0.05)	$(0.05)
Net loss per share, diluted	$(0.05)	$(0.05)
Weighted-average shares used in calculating net loss per share, basic	130,920,971	135,489,194
Weighted-average shares used in calculating net loss per share, diluted	130,920,971	135,489,194
Comprehensive loss:
Net loss	$(6,169)	$(6,807)
Foreign currency translation adjustment, net of tax	(244)	(42)
Unrealized (loss) gain on marketable securities	(35)	152
Net comprehensive loss	$(6,448)	$(6,697)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.